These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 30234515)

  • 41. Canagliflozin-Associated Acute Pancreatitis.
    Verma R
    Am J Ther; 2016; 23(3):e972-3. PubMed ID: 25187092
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Postoperative extremity gangrene in a patient with type 2 diabetes taking SGLT2 inhibitors: A case report.
    Wong YC; Liu KL; Lee CL
    Medicine (Baltimore); 2021 Apr; 100(16):e25590. PubMed ID: 33879720
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Non-occlusive Mesenteric Ischemia with Diabetic Ketoacidosis and Lactic Acidosis Following the Administration of a Sodium Glucose Co-transporter 2 Inhibitor.
    Gocho N; Aoki E; Okada C; Omura K; Hirashima T; Suzuki N; Tanaka H; Omori Y
    Intern Med; 2016; 55(13):1755-60. PubMed ID: 27374678
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives.
    Qiu H; Novikov A; Vallon V
    Diabetes Metab Res Rev; 2017 Jul; 33(5):. PubMed ID: 28099783
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants.
    Devineni D; Manitpisitkul P; Murphy J; Skee D; Wajs E; Mamidi RN; Tian H; Vandebosch A; Wang SS; Verhaeghe T; Stieltjes H; Usiskin K
    Clin Pharmacol Drug Dev; 2015; 4(3):226-36. PubMed ID: 27140803
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Generalized Intense Pruritus During Canagliflozin Treatment: Is it an Adverse Drug Reaction?
    Vasapollo P; Cione E; Luciani F; Gallelli L
    Curr Drug Saf; 2018; 13(1):38-40. PubMed ID: 27048192
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Metabolic acidosis of surprising origin in a 61-year-old female patient].
    Koyro TF; Thottakara T; Huber TB; Harendza S
    Internist (Berl); 2021 May; 62(5):549-554. PubMed ID: 33326044
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Outcome studies on SGLT-2 inhibitors].
    Seufert J; Laubner K
    Internist (Berl); 2019 Sep; 60(9):903-911. PubMed ID: 31375850
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study.
    Leiter LA; Yoon KH; Arias P; Langslet G; Xie J; Balis DA; Millington D; Vercruysse F; Canovatchel W; Meininger G
    Diabetes Care; 2015 Mar; 38(3):355-64. PubMed ID: 25205142
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Perioperative Ketoacidosis under SGLT2-Inhibitors].
    Buck S; Russo SG
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2021 Oct; 56(10):704-708. PubMed ID: 34704247
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis.
    Pfeifer M; Townsend RR; Davies MJ; Vijapurkar U; Ren J
    Cardiovasc Diabetol; 2017 Feb; 16(1):29. PubMed ID: 28241822
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Empagliflozin-associated postoperative mixed metabolic acidosis. Case report and review of pathogenesis.
    Sitina M; Lukes M; Sramek V
    BMC Endocr Disord; 2023 Apr; 23(1):81. PubMed ID: 37060078
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ketoacidosis Due to Empagliflozin, a Paradigm Shift: Case Report and Review of Literature.
    Hernandez-Quiles C; Ramirez-Duque N; Acosta-Delgado D
    Curr Diabetes Rev; 2019; 15(4):259-262. PubMed ID: 30047331
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus.
    Davies MJ; Trujillo A; Vijapurkar U; Damaraju CV; Meininger G
    Diabetes Obes Metab; 2015 Apr; 17(4):426-9. PubMed ID: 25600248
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
    Lavalle-González FJ; Eliaschewitz FG; Cerdas S; Chacon Mdel P; Tong C; Alba M
    Curr Med Res Opin; 2016; 32(3):427-39. PubMed ID: 26579834
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Possible synergistic effect of metformin and enalapril on the development of hyperkaliemic lactic acidosis.
    Franzetti I; Paolo D; Marco G; Emanuela M; Elisabetta Z; Renato U
    Diabetes Res Clin Pract; 1997 Dec; 38(3):173-6. PubMed ID: 9483383
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Coma in type 2 diabete mellitus on metformin treatment].
    Renard C; Tellal S; Fevre G; Ragot C; Vest P; Foissaud V; Renaudeau C
    Ann Biol Clin (Paris); 2003; 61(1):84-7. PubMed ID: 12604391
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Kawalec P; Mikrut A; Łopuch S
    Diabetes Metab Res Rev; 2014 May; 30(4):269-83. PubMed ID: 24829965
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sodium-glucose cotransporter 2 inhibitors and diabetic ketoacidosis.
    Bloomgarden ZT
    J Diabetes; 2016 Mar; 8(2):175-6. PubMed ID: 26611882
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.